Compare iShares MSCI South Africa ETF (EZA) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Africa ETF vs Mesoblast Limited — how do they compare? iShares MSCI South Africa ETF trades at $62.57 (market cap $466.20M), while Mesoblast Limited trades at $13.8 (market cap $1.81B). The key difference: Mesoblast Limited is far larger — about 3.9× iShares MSCI South Africa ETF's market cap, and Mesoblast Limited is more actively traded (240,620 versus 152,369). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Africa ETF for 70 Days and Mesoblast Limited for 14 Days on average.
| EZA | MESO | |
|---|---|---|
Market Cap | $466.20M | $1.81B |
Volume | 152,369 | 240,620 |
Sector | Broad Market / Factor | Health |
52-Week High | $81.60 | $20.96 |
52-Week Low | $60.43 | $13.19 |
Typical Hold Time | 70 Days | 14 Days |
Enterprise Value | — | $1.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EZA trades at $62.29, down 2.15% today, with a bearish technical signal driven by moving averages. The ETF's portfolio faces headwinds from global reflation impacting its heavy exposure to South African gold, banking, and platinum group metals. Key oscillators like the 6-day and 12-day relative strength index indicate oversold conditions, suggesting potential for a near-term bounce, but the average directional index signals a strong downtrend.
The outlook is cautious due to macroeconomic pressures on constituent companies, with risks from higher capital costs and commodity price volatility. Investment opportunity hinges on a reversal in global yield curves and commodity markets, but current sentiment remains negative amid sell-side dominance and lack of positive fundamental catalysts.
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI South Africa ETF
EZA is a country-specific ETF that tracks the South African equity market. It provides exposure to large and mid-cap companies across key sectors like materials and financials, with top holdings such as AngloGold Ashanti and Naspers.
Read more on EZA →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
